ArticlePloS one2019
Selected serum microRNA, abdominal aortic calcification and risk of osteoporotic fracture.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Postmenopausal Osteoporosis, Endothelial Dysfunction, and Cardiovascular Risk.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2026Article
- The diagnostic and therapeutic potential of miR-3149 in osteoporotic fractures through SMAD4.Journal of orthopaedic surgery and research · 2025Article
- Deep learning-based automated quantification system for abdominal aortic calcification: multicenter cohort study for algorithm development and clinical validation.Frontiers in cardiovascular medicine · 2025Article
- Association of monocyte and lymphocyte ratio with risk of abdominal aortic calcification.PloS one · 2025Article
- Common miRNAs of Osteoporosis and Fibromyalgia: A Review.International journal of molecular sciences · 2023Review
- Periostin in Osteoporosis and Cardiovascular Disease.Journal of the Endocrine Society · 2023Review
- MicroRNAs: emerging biomarkers and therapeutic targets of bone fragility in chronic kidney disease.Clinical kidney journal · 2023Review
- Study on Omentin-1 and miR-502-3p in osteoporotic fracture.Journal of musculoskeletal & neuronal interactions · 2021Article
- Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?International journal of molecular sciences · 2020Review
- Epigenetic Regulation of Skeletal Tissue Integrity and Osteoporosis Development.International journal of molecular sciences · 2020Review
- The Role of Micro RNA and Long-Non-Coding RNA in Osteoporosis.International journal of molecular sciences · 2020Review
- Circulating miRNAs: A New Opportunity in Bone Fragility.Biomolecules · 2020Review
- The Epigenetic Landscape of Vascular Calcification: An Integrative Perspective.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextMicroRNA (miRNA) regulate post-transcriptionally the expression of osteogenesis and angiogenesis associated genes and emerge as potential non-invasive biomarkers in vascular and bone diseases. Severe abdominal aortic calcification (AAC) is associated with higher risk of cardiovascular event and of fragility fracture.
objectiveTo identify miRNA linked to the aggravation of AAC and to incident osteoporotic fracture.
designPostmenopausal women (>50 years) with available serum at inclusion and data for each outcome (Kauppila score and incident fracture) were selected from the OFELY prospective cohort. We conducted a case-control study in 434 age-matched women, 50% with incident osteoporotic fracture over 20 years of follow-up and a second study in 183 women to explore AAC over 17 years.
methodsSerum expression of three miRNA involved in vascular calcification and bone turnover regulation (miRs-26a-5p,-34a-5p, and -223-5p) was quantified at baseline by TaqMan Advanced miRNA technology and expressed by relative quantification. Outcomes were the association of miRNA levels with (1) incident osteoporotic fractures during 20 years, (2) AAC aggravation during 17 years.
resultsMiRNA level was not associated with incident fractures (miR-26a-5p: 1.06 vs 0.99, p = 0.07; miR-34a-5p: 1.15 vs 1.26, p = 0.35; miR-223a-5p: 1.01 vs 1.05, p = 0.32). 93 women had an increase in Kauppila score over 17 years while 90 did not. None of the miRNAs was associated with an aggravation in AAC (miR-26a-5p: 1.09 vs 1.10, p = 0.95; miR-34a-5p: 0.78 vs 0.73, p = 0.90; miR-223-5p: 0.97 vs 0.78, p = 0.11).
conclusionsCirculating miR-26a-5p, -34a-5p and -223-5p are not significantly associated with incident fracture and AAC aggravation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.